# OnCo record langerhans-cell-histiocytosis (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/langerhans-cell-histiocytosis/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "langerhans-cell-histiocytosis" ;
  schema:name "Langerhans cell histiocytosis (LCH)"@en ;
  schema:alternateName "LCH"@en, "Histiocytosis X"@en, "Eosinophilic granuloma"@en, "Hand-Schuller-Christian disease"@en, "Letterer-Siwe disease"@en ;
  schema:description "Langerhans cell histiocytosis is a disorder in which a small group of immune cells with a faulty growth signal (most often a BRAF mutation) pile up in bone, skin, pituitary or organs. It ranges from a single bone lesion that heals after biopsy to a life-threatening disease of infants. A year of gentle chemotherapy cures most children, and BRAF or MEK inhibitors rescue those with resistant disease."@en ;
  schema:url <https://onco.cc/cancers/langerhans-cell-histiocytosis/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Langerhans_cell_histiocytosis> ;
  schema:citation <https://www.cancer.gov/types/langerhans/hp/langerhans-treatment-pdq>, <https://doi.org/10.1182/blood-2012-09-455774>, <https://doi.org/10.1200/JCO.19.00456>, <https://histiocytesociety.org/> ;
  onco:tag "nci-coverage", "paediatric", "haematologic" ;
  onco:related <https://onco.cc/cancers/histiocytoses/>, <https://onco.cc/cancers/bpdcn/>, <https://onco.cc/cancers/aml/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:targets <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/cladribine/> ;
  onco:companies <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:institutions <https://onco.cc/institutions/histiocyte-society/>, <https://onco.cc/institutions/siop-europe/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/late-effects/> ;
  onco:trials <https://onco.cc/trials/lch-iii/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:pipeline <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/trials/lch-iii/> ;
  onco:standardOfCare <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/trials/lch-iii/>, <https://onco.cc/drugs/cladribine/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/technologies/mri/> .